95 related articles for article (PubMed ID: 2825959)
1. Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
Creagan ET; Long HJ; Frytak S; Moertel CG
Cancer; 1988 Jan; 61(1):19-22. PubMed ID: 2825959
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
Creagan ET; Frytak S; Long HJ; Kvols LK
Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.
Feun LG; Savaraj N; Hung S; Reddy R; Jeffers L; Benedetto P; Livingstone AS; Ardalan B; Levi JU; Parker T
Am J Clin Oncol; 1994 Oct; 17(5):393-5. PubMed ID: 8092109
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
Sarosy GA; Brown TD; Von Hoff DD; Spiegel RJ; Golando JP; Beougher KL; Kuhn JG; Kisner DL
Cancer Res; 1986 Oct; 46(10):5368-71. PubMed ID: 3756887
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.
Kurzrock R; Rosenblum MG; Quesada JR; Sherwin SA; Itri LM; Gutterman JU
J Clin Oncol; 1986 Nov; 4(11):1677-83. PubMed ID: 3095504
[TBL] [Abstract][Full Text] [Related]
7. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
Kardinal CG; Moertel CG; Wieand HS; Schutt AJ; O'Connell MJ; Wright K; Wiesenfeld M; Tschetter LK; Krook JE
Cancer; 1993 Apr; 71(7):2187-90. PubMed ID: 8384064
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
9. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
Feun LG; O'Brien C; Molina E; Rodriguez M; Jeffers L; Schiff ER; Marini A; Savaraj N; Ardalan B
J Cancer Res Clin Oncol; 2003 Jan; 129(1):17-20. PubMed ID: 12618896
[TBL] [Abstract][Full Text] [Related]
10. Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin.
Von Hoff DD; Sarosy G; Brown TD; Kuhn JG; Kisner DL
Semin Oncol; 1986 Sep; 13(3 Suppl 2):72-7. PubMed ID: 3764442
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum.
Dhingra K; Talpaz M; Dhingra HM; Ajani JA; Rothberg JM; Gutterman JU
Invest New Drugs; 1991 Feb; 9(1):37-9. PubMed ID: 1851142
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
Lai CL; Wu PC; Lok AS; Lin HJ; Ngan H; Lau JY; Chung HT; Ng MM; Yeoh EK; Arnold M
Br J Cancer; 1989 Dec; 60(6):928-33. PubMed ID: 2557881
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma.
Creagan ET; Loprinzi CL; Ahmann DL; Schaid DJ
Cancer; 1988 Dec; 62(12):2472-4. PubMed ID: 3142675
[TBL] [Abstract][Full Text] [Related]
15. [Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon].
Amiot X; Grangé JD; Boudghene F; Lamarque D; Lotz JP; Izrael V; Bodin F
Ann Gastroenterol Hepatol (Paris); 1991 Oct; 27(5):211-4. PubMed ID: 1660687
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy with recombinant interleukin-2 and adriamycin in primary hepatocellular carcinoma.
Chien CH; Hsieh KH; Yang PM
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 May; 24(2):201-12. PubMed ID: 1649735
[TBL] [Abstract][Full Text] [Related]
17. Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study.
Lotz JP; Grange JD; Hannoun L; Boudghene F; Amiot X; Lamarque D; Andre T; Esteso A; Bellaiche A; Bouleuc C
Eur J Cancer; 1994; 30A(9):1319-25. PubMed ID: 7528030
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon.
Green MD; Speyer JL; Hochster HS; Liebes LF; Dunleavy S; Widman T; Wernz JC; Blum RH; Spiegel RJ; Muggia FM
Cancer Res; 1988 May; 48(9):2574-8. PubMed ID: 3356017
[TBL] [Abstract][Full Text] [Related]
19. Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC).
Kountouras J; Boura P; Karolides A; Zaharioudaki E; Tsapas G
Hepatogastroenterology; 1995 Feb; 42(1):31-6. PubMed ID: 7782031
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]